| Trial ID: | L2432 |
| Source ID: | NCT02655757
|
| Associated Drug: |
Sitagliptin
|
| Title: |
Effect of Sitagliptin on Progression of Coronary Intermediate Lesion
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Atherosclerosis|Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Sitagliptin|DRUG: Placebo
|
| Outcome Measures: |
Primary: Changes in late lumen loss of target lesion, A coronary intermediate lesion in Patients with coronary heart disease complicated with Type 2 Diabetes was measure with 3D QCA(3D Quantitative Coronary Angiography). To measure the changes in target lumen at 12 months., Changes from baseline in late lumen loss of target lesion at 12 months | Secondary: Incidence rate of MACE, MACE include composite of death, myocardial infarction, or target-vessel revascularization., Incidence rate of MACE from baseline to 12 months
|
| Sponsor/Collaborators: |
Sponsor: Li Bo
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
120
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2015-12
|
| Completion Date: |
2017-03-10
|
| Results First Posted: |
|
| Last Update Posted: |
2018-01-25
|
| Locations: |
The General Hospital of PLA, Beijing, Beijing, 100853, China
|
| URL: |
https://clinicaltrials.gov/show/NCT02655757
|
